[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][=C][Branch1][#C][C][=C][C][=C][Ring1][=Branch1][C][Branch1][C][F][Branch1][C][F][F][C][N][C][=Branch2][Ring1][=C][=N][C][=C][Branch2][Ring1][Ring1][C][=C][Branch1][#Branch1][C][=C][Ring1][=Branch1][Ring1][=Branch2][N][C][C][O][C][C][Ring1][=Branch1][C][=Branch1][C][=O][O][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells."}]